论文部分内容阅读
异丁基哌嗪力复霉素系四川抗菌素工业研究所于1976年试制成功,经过多年的体内外抗菌作用研究,临床前药理研究和临床试用,均证实它具有抗菌谱广,作用强,毒副反应小的优点,特别是对结核,麻风杆菌具有较强的抗菌作用。临床试用于治疗结核病、麻风病、化脓性皮肤病,以及沙眼、结膜炎等疾病均取得满意的疗效,与甲哌力复霉素相比具有抗菌力强,对肝脏损害小价格便宜的特点,是一种较理想的新抗结核药。 我们在研究该药的体内过程中,发现在人和不同动物体内该药的血药半衰期有很大差别为了进一步证实这个问题,确保临床用药的安全性和研究异丁基哌嗪力复霉素的体内过程,本文通过测量小鼠口服[~3H]
Isobutylpiperazine force of daunorubicin Sichuan Institute of antibiotics in 1976 trial success, after years of in vitro and in vivo antibacterial activity, preclinical pharmacological studies and clinical trials, all confirmed that it has broad antibacterial spectrum, the role of strong, toxic Side effects of small advantages, especially for tuberculosis, Leprosy has a strong antibacterial effect. Clinical trial for the treatment of tuberculosis, leprosy, suppurative skin disease, and trachoma, conjunctivitis and other diseases have achieved satisfactory results, compared with mepivacaine with antibacterial strong, low cost of liver damage characteristics, Is a more ideal new anti-TB drugs. We in the study of the drug in vivo process and found that in humans and different animals in the blood half-life of the drug there is a big difference in order to further confirm this problem, to ensure the safety of clinical medication and isobutyryl piperazine ribosulfan In vivo process, this article by measuring mice oral [~ 3H]